Recent News

• 11.10.2025 - aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
• 11.06.2025 - aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
• 09.30.2025 - aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
• 09.30.2025 - EFZO-FIT™: The Largest Ever Interventional Trial in Pulmonary Sarcoidosis
• 09.30.2025 - aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
• 09.30.2025 - aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
• 09.15.2025 - aTyr Pharma Conference Call
• 09.15.2025 - aTyr Pharma Conference Call
• 09.15.2025 - aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
• 09.15.2025 - aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Recent Filings

• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.15.2025 - 8-K Current report
• 09.15.2025 - EX-99.1 EX-99.1